Editorial Comment: Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Int Braz J Urol
.
2021 Jan-Feb;47(1):200-201.
doi: 10.1590/S1677-5538.IBJU.2021.01.08.
Author
Felipe Lott
1
Affiliation
1
Instituto Nacional do Câncer - INCA, Rio de Janeiro, RJ, Brasil.
PMID:
33047929
PMCID:
PMC7712714
DOI:
10.1590/S1677-5538.IBJU.2021.01.08
No abstract available
Publication types
Editorial
Comment
MeSH terms
Androgen Antagonists / therapeutic use
Androstenes*
Hormones
Humans
Male
Prostatic Neoplasms* / drug therapy
Substances
Androgen Antagonists
Androstenes
Hormones
abiraterone